Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Supreme Court Should Resolve False Claims Act Causation Question
Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Regeneron stock dips as court denies Eylea patent stay
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Yahoo Finance11d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...